In January 2026, Autobio officially launched its Sikun series gene sequencing analyzers (Sikun2000, Sikun1000, Sikun500) into the clinical market following NMPA registration in December 2025. The company's AI-powered clinical laboratory decision support system has been installed in over 30 hospitals as of February 2026. On April 23, 2026, the company disclosed its 2025 annual report and Q1 2026 quarterly report.
Company Profile (Updated April 2026)
Autobio Diagnostics Co., Ltd. (郑州安图生物工程股份有限公司) is one of China's leADINg in vitro diagnostic (IVD) companies, dedicated to providing comprehensive "product + service" integrated solutions for medical laboratories. Founded in 1998 in Zhengzhou, Henan Province, china, the company was formerly known as Lifeclone Diagnostics Co., Ltd. before changing its name to Autobio Diagnostics in 2003. The company was listed on the Shanghai Stock Exchange on September 1, 2016 (Stock Code: 603658), with an IPO price of RMB 14.58 per share.
Autobio specializes in the research, development, production, and sale of clinical diagnostic products, with core business segments covering immunoassay, microbiology, biochemistry, molecular diagnostics, and expanding into sequencing, mass spectrometry, and intelligent medical laboratory solutions. The company's products have entered markets across the Middle East, Asia, Europe, the Americas, and Africa.
Core Mission: "Committed to the popularization and improvement of medical laboratory technology, serving human health." The company strives to provide users with products and services offering superior performance-to-price and quality-to-price ratios.
2025 Annual Financial Performance
Full-Year 2025 Results
Revenue: RMB 4.226 billion (42.26亿元), down 5.47% year-over-year
Net Profit AttributAble to Shareholders: RMB 1.068 billion (10.68亿元), down 10.59% YoY
Non-recurring Net Profit: RMB 998 million (9.98亿元), down 9.14% YoY
Total Profit: RMB 1.223 billion (12.23亿元), down 5.14% YoY
Operating Cash Flow: RMB 1.342 billion (13.42亿元), up 2.47% YoY
Basic EPS: RMB 1.87, down 9.66% YoY
Weighted Average ROE: 12.25% (down 1.67 percentage points YoY)
R&D Expenses: RMB 555 million (5.55亿元)
Total Assets (Year-End 2025): RMB 12.29 billion (122.9亿元), up 3.49% YoY
Net Assets Attributable to Shareholders: RMB 8.926 billion (89.26亿元), up 3.59% YoY
Quarterly Breakdown (2025)
- Q1: Revenue RMB 996 million; Net Profit RMB 270 million
- Q2: Revenue RMB 1.064 billion; Net Profit RMB 301 million
- Q3: Revenue RMB 1.067 billion; Net Profit RMB 289 million
- Q4: Revenue RMB 1.100 billion; Net Profit RMB 209 million
2024 Comparative Performance
- Revenue: RMB 4.471 billion (44.71亿元), up 0.62% YoY
- Net Profit: RMB 1.194 billion (11.94亿元), down 1.89% YoY
- Total Assets: RMB 11.875 billion (118.75亿元)
- Net Assets: RMB 8.617 billion (86.17亿元)
2026 Q1 Financial Performance
Q1 2026 Results (Latest)
Revenue: RMB 992 million (9.92亿元), down 0.37% year-over-year
Total Profit: RMB 262 million (2.62亿元), down 13.29% YoY
Net Profit Attributable to Shareholders: Approximately RMB 236 million (2.36亿元)
Non-recurring Net Profit: RMB 232 million (2.32亿元), down 9.52% YoY
Basic EPS: RMB 0.41, down 12.77% YoY
Weighted Average ROE: 2.62% (down 0.47 percentage points YoY)
Operating Cash Flow: Net inflow of RMB 147 million (1.47亿元)
Operating Cost: RMB 331 million (3.31亿元)
R&D Expenses: RMB 134 million (1.34亿元)
Gross Margin (Q1 2026): Approximately 66.64%
Q1 2026 Balance Sheet
Total Assets: RMB 12.242 billion (122.42亿元)
Total Liabilities: RMB 2.987 billion (29.87亿元)
Net Assets Attributable to Shareholders: Approximately RMB 9.162 billion (91.62亿元)
Cash and Cash Equivalents: RMB 789 million (7.89亿元)
Profit Distribution Plan
The company's 2025 annual profit distribution plan, approved by the Board of Directors:
- Cash Dividend: RMB 1.31 per share (tax inclusive), equivalent to RMB 13.1 per 10 shares
- Total Dividend Payout: Approximately RMB 749 million (7.49亿元)
- Total Shares: 571,424,768 shares
- Retained Earnings (Parent Company): RMB 3.296 billion (32.96亿元)
Core Products and Technology Platforms
Immunoassay (Chemiluminescence)
- AutoLumo S900 / A1860: Compact automated chemiluminescence analyzers for small and medium-sized laboratories
- AutoLumo A6200 / A6600: High-throughput automated immunoassay analyzers
- AutoLumo A2000 Plus: Large-volume automated chemiluminescence immunoassay system
- PHOmo / LUmo: Microplate readers and luminometers
- iWO / iWO-960: Microplate washers
Microbiology
- AutoMic-I60: Automated microbial identification and antibiotic susceptibility testing system
- AutoStreak S1800: Microbial sample pretreatment system
- Autof T Series / MALDI-TOF MS: Rapid pathogenic bacteria identification systems
- AutoMimo 1200: Automated pipetting efficiency optimization instrument
- BC60 / BC120: Automated blood culture and bacterial detection systems
- Blood culture bottles and mycoplasma testing reagents
Molecular Diagnostics
- AutoMolec 1600: Integrated automated molecular diagnostics analyzer
- AutoMolec 3000: In vitro molecular detection instrument
- Respiratory pathogen detection kits (PCR-fluorescence probe method), including influenza A/B, RSV, parainfluenza, metapneumovirus, mycoplasma pneumoniae, chlamydia pneumoniae, adenovirus, and COVID-19
Coagulation and Biochemistry
- Ci-120x / Ci-310: Benchtop coagulation analyzers
- Autolas Bi 1000 / Bi 2600: Automated biochemistry analyzers
- AutoChem B861 / B2000: Automated biochemistry systems
Gene Sequencing (Launched 2026)
- Sikun2000, Sikun1000, Sikun500: Gene sequencing analyzers developed by subsidiary Sikun Bio, receiving NMPA medical device registration in December 2025 and entering the clinical market in January 2026
- This marks Autobio's strategic expansion from traditional biochemical immunoassay and morpHological microbiology testing into precision molecular diagnostics
AI-Powered Solutions
- AI Clinical Laboratory Decision Support System: Designed to enhance clinical and laboratory accuracy and operational efficiency, supporting intelligent laboratory services. As of February 2026, the system has been installed in over 30 hospitals and seamlessly integrated with existing laboratory equipment and LIS systems
- The company was added to the "AI Application" concept category by Tonghuashun in March 2026
2025-2026 Latest Developments
Corporate Events
- April 23, 2026: Disclosed 2025 annual report and Q1 2026 quarterly report; reappointed Zhongqin Wanxin CPA as the 2026 annual audit institution
- May 13, 2026: Annual General Meeting scheduled to review 2025 board reports, profit distribution plan, and executive compensation
- March 31, 2026: Announcement of new medical device registration certificates obtained
- December 16, 2025: Sikun series gene sequencing analyzers new product launch conference held
- June 2025: Subsidiary Zhengzhou Autobio Mobidiag Molecular Diagnostics Technology Co., Ltd. (65% owned, joint venture with Mobidiag) completed dissolution and deregistration following arbitration settlement
Executive Appointments (2024-2025)
- Wang Dongdong (37 years old): Appointed as Chief Financial Officer in April 2025
- Liu Wei (49 years old): Appointed as Employee Representative Director in November 2025
- Zhang Ruifeng (49 years old): Appointed as Executive Vice General Manager and Non-Independent Director in October 2024
- Qiao Hailing: Nominated as Independent Director candidate in January 2025
Shareholder and Equity Activities
- Chairman Miao Yongjun: Completed cumulative share purchases of approximately RMB 21 million by December 2024
- Share Repurchase (2024): Repurchased and cancelled 5.261 million shares at an average price of RMB 46.24
- Controlling Shareholder: Zhengzhou Autobio Industrial Group Co., Ltd. (originally held 55.13%; underwent corporate division in 2021, splitting 15% equity into three new companies)
Company Basic Information
Corporate Overview
Company Full Name: Autobio Diagnostics Co., Ltd. (郑州安图生物工程股份有限公司)
Former Name: Lifeclone Diagnostics Co., Ltd.
Stock Code: 603658 (Shanghai Stock Exchange Main Board)
Founded: 1998
Name Changed: 2003
Listed: September 1, 2016
IPO Price: RMB 14.58
Registered Address: No. 87 Jingbei 1st Road, Zhengzhou Economic and Technological Development Zone, Henan, China
Legal Representative / General Manager: Yang Zengli
Chairman / Controlling Shareholder / Actual Controller: Miao Yongjun
Board Secretary: Fang Ruikuan
CFO: Wang Dongdong
Company Type: Public Listed Company
Industry: Medical Devices - In Vitro Diagnostics (IVD)
Employees: Approximately 5,773
Registered Capital: RMB 571.425 million
Total Shares: 571,424,768 shares
Official Website: www.autobio.com.cn
Email: autobio@autobio.com.cn
Telephone: +86-0371-86506868
Audit Institution: Zhongqin Wanxin Certified Public Accountants (Special General Partnership)
Subsidiaries and Affiliates
- ADVANBIO, INC. (USA, 100%)
- Shanghai Autobio Biotechnology Co., Ltd. (100%)
- Shanghai Biaoyuan Biotechnology Co., Ltd. (87%)
- Yunnan Autobio Yinuo Technology Co., Ltd. (51%)
- Beijing Autobio Bioengineering Co., Ltd. (100%)
- Autobio Laboratory Instruments (Zhengzhou) Co., Ltd. (100%)
- Autobio Diagnostics (Hong Kong) Co., Ltd. (100%)
- Hebei Autobio Jiuhe Medical Technology Co., Ltd. (51%)
- Shenzhen Autobio Bioengineering Co., Ltd. (100%)
- Zhengzhou Sikun Bioengineering Co., Ltd. (100%, gene sequencing)
- Zhengzhou Yimeinuo Biotechnology Co., Ltd. (100%)
- Zhengzhou Autobio Technology Development Co., Ltd. (100%)
- Zhengzhou Autobio Mobidiag Molecular Diagnostics Technology Co., Ltd. (65%, dissolved June 2025)
- Zhengzhou Gongdong Medical Devices Co., Ltd. (affiliate)
- Zhengzhou Jiuhe Medical Laboratory Co., Ltd. (affiliate)
Global Market Layout
Domestic Market
As a leading domestic IVD manufacturer, Autobio serves medical laboratories across China with a comprehensive product portfolio. The company's chemical luminescence business is Primarily distributed in the Asia-Pacific region, while its microbiology business extends across Europe and international markets.
International Market
Autobio products have entered markets in the Middle East, Asia, Europe, the Americas, and Africa. The company expects overseas business to maintain high-speed growth over the next 3-5 years.
Main Competitors
- Mindray (Shenzhen Mindray Bio-Medical Electronics Co., Ltd.)
- Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)
- Maccura Biotechnology
- KHB (Shanghai Kehua Bio-Engineering Co., Ltd.)
- International Giants: Roche, Abbott, Siemens, Danaher (dominating China's high-end IVD market)
2026 Outlook and Strategic Priorities
Strategic Focus Areas
- Precision Diagnostics: Accelerate the commercialization of gene sequencing platforms (Sikun series) to expand from traditional IVD into precision molecular diagnostics
- AI Integration: Expand deployment of the AI clinical decision support system to more hospitals, driving intelligent laboratory transformation
- Product Innovation: Maintain high R&D investment to develop new diagnostic reagents and instruments across immunoassay, microbiology, and molecular platforms
- Overseas Expansion: Strengthen international market penetration, particularly in Asia-Pacific, Europe, and emerging markets
- Operational Efficiency: Address accounts receivable and inventory management challenges exacerbated by DRG/DIP healthcare payment reforms and IVD centralized procurement
Risk Factors
- Policy Pressure: Ongoing DRG/DIP payment reforms and IVD centralized procurement continue to pressure pricing and hospital payment cycles
- Accounts Receivable: High accounts receivable balance (RMB 1.097 billion at Q1 2025, representing 91.81% of annual net profit) with extended collection periods
- Revenue Decline: 2025 full-year revenue declined for the first time in recent years, reflecting industry-wide headwinds
- Intense Competition: Domestic peer competition and international giant dominance in high-end markets
Contact Information
Headquarters
Address: No. 87 Jingbei 1st Road, Zhengzhou Economic and Technological Development Zone, Henan, China
Postal Code: 450016
Tel: +86-0371-86506868
Email: autobio@autobio.com.cn
Website: www.autobio.com.cn
Investor Relations
Stock Exchange: Shanghai Stock Exchange
Stock Code: 603658
Information Disclosure: www.sse.com.cn
Keywords: Autobio Diagnostics,安图生物,603658,IVD,In Vitro Diagnostics,Immunoassay,Chemiluminescence,Microbiology,Molecular Diagnostics,Gene Sequencing,Sikun,AutoLumo,MALDI-TOF,Blood Culture,AI Laboratory,Zhengzhou,Miao Yongjun,Yang Zengli,Medical Laboratory,Intelligent Lab,Shanghai Stock Exchange
